

# Inflammatory Bowel Disease Referral Form

Referral for Medication and Patient Management Program

Phone: 877 385 0535 Fax: 877 326 2856



V.12.13.16.A

## Patient Demographics

Name: \_\_\_\_\_  M  F  
DOB: \_\_\_\_\_ SS#: \_\_\_\_\_  
Phone: \_\_\_\_\_ 2<sup>nd</sup> Phone: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Primary language, if other than English: \_\_\_\_\_

**\*\*Please fax a copy (front and back) of the patient's insurance card as well as any relevant clinical notes/documents\*\***

## Provider Information

Prescriber: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
Address: \_\_\_\_\_  
NPI: \_\_\_\_\_ Office contact: \_\_\_\_\_  
This is a:  New Rx  Refill  
Training by:  Prescriber's office  Pharmacy to facilitate  Not needed  
Deliver first fill to:  Prescriber's office  Patient  Other: \_\_\_\_\_

## Clinical Information

### Diagnosis (ICD-10 Code):

#### Crohn's Disease:

- Crohn's Disease (Small Intestine) (K50.0)
- Crohn's Disease (Large Intestine) (K50.1)
- Crohn's Disease (Both Intestines) (K50.8)
- Crohn's Disease, unspecified (K50.9)
- Other: \_\_\_\_\_

#### Ulcerative Colitis:

- Ulcerative Pancolitis (K51.0)
- Ulcerative Proctitis (K51.2)
- Ulcerative Rectosigmoiditis (K51.3)
- Left Sided Colitis (K51.5)
- Other Ulcerative Colitis (K51.8)
- Ulcerative Colitis, Unspecified (K51.9)
- Other: \_\_\_\_\_

Date of negative TB test: \_\_\_\_\_  TB test pending, will fax results

HBV negative or treated:  Yes  No

Patient weight: \_\_\_\_\_ Height: \_\_\_\_\_

Allergies: \_\_\_\_\_

Prior treatment, treatment dates, & reason for discontinuation: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Comorbid conditions: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Other notes: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

## Prescription Information

<u>Medication</u>	<u>Directions</u>	<u>Quantity</u>	<u>Refills</u>
<input type="checkbox"/> Cimzia 200mg (certolizumab)	<input type="checkbox"/> Induction: Inject 400mg SQ week 0, week 2, and week 4. Maintenance: <input type="checkbox"/> Inject 200mg SQ every OTHER week. <input type="checkbox"/> Inject 400mg SQ every 4 weeks.	6 syringes <input type="checkbox"/> 2 syringes <input type="checkbox"/> Other: _____	Zero _____ _____
<input type="checkbox"/> Humira 40mg (adalimumab)	<input type="checkbox"/> Induction: Inject 160mg SQ on day 1, 80mg on day 15, then 40mg every OTHER week thereafter. <input type="checkbox"/> Maintenance: Inject 40mg SQ every OTHER week. <input type="checkbox"/> Other: _____	<input type="checkbox"/> 6 pens/syringes <input type="checkbox"/> 2 pens/syringes <input type="checkbox"/> Other: _____	Zero _____ _____
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> Induction: Inject 200mg SQ week 0, 100mg week 2, then 100mg every 4 weeks thereafter. <input type="checkbox"/> Maintenance: Inject 100mg SQ every 4 weeks. <input type="checkbox"/> Other: _____	3 pens/syringes <input type="checkbox"/> 1 pen/syringe <input type="checkbox"/> Other: _____	Zero _____ _____
<input type="checkbox"/> Stelara (ustekinumab)	Maintenance: Inject 90mg SQ every 8 weeks, beginning 8 weeks after IV loading dose.	<input type="checkbox"/> 1 syringe <input type="checkbox"/> Other: _____	_____ _____

Please note, to increase adherence and patient acceptance, all medications will be dispensed as pen-type injectors unless unavailable or otherwise specified.

**Provider Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

My signature for this prescription also authorizes OptiMed Pharmacy and its representatives to act as an agent of mine to initiate and execute the patient's insurance prior authorization process. **Confidentiality statement:** This message is intended only for the individual or institution to which it is addressed. This may contain information, which is confidential, privileged, and/or proprietary. This information may be exempt from disclosure under applicable laws including but not limited to HIPAA. If you are not the intended recipient, please note you are strictly prohibited from distributing, copying, or disseminating this information. If you received this information in error please notify the sender noted above and destroy all transmitted material.